Liposomal Bupivacaine After Arthroscopic Rotator Cuff Repair

Completed · Phase 4 · Has a placebo group

Conditions studied: Rotator Cuff Tear

In brief

Liposomal bupivacaine, a long-acting form of bupivacaine, has been found to be effective for postoperative pain control after total knee, total hip and total shoulder arthroplasty. We are conducting a randomized, controlled trial to evaluate pain control after arthroscopic rotator cuff repair in ambulatory patients, comparing standard care in the control group, with standard care plus the addition of injection of liposomal bupivacaine in the experimental group.

Key facts

Study ID

NCT03149887

Run by

Steven Orebaugh

People needed

54

Starts

2017-12-05

Expected to finish

2019-03-01

Last updated by the study team

2020-01-23

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adult patients up to age 65 years, undergoing elective, ambulatory, arthroscopic rotator cuff repair.

You may not qualify if…

• Pregnancy, coagulopathy, allergy to bupivacaine, renal failure, hepatic insufficiency, and/or inappropriate candidate for usual therapy (specifically, if unable to receive the usual preoperative interscalene nerve block: preexisting nerve injury on side of surgery, refusal of nerve block, infection at site of nerve block).

Where it is running

• University of Pittsburgh Medical Center-Southside/Mercy — Pittsburgh, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.